You are here

  • Home
  • Archive
  • Volume 79, Issue 7
  • Antisynthetase antibodies in clinical laboratories: the importance of clinical correlation and indirect immunofluorescence. Response to: Comment on: ‘Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodie…

Article Text

Article menu

Download PDFPDF

Correspondence response
Antisynthetase antibodies in clinical laboratories: the importance of clinical correlation and indirect immunofluorescence. Response to: Comment on: ‘Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria’ by Greco et al’ by Knitza et al
Free
  1. Martin Greco1,
  2. Mª Jesus García de Yébenes2,
  3. Inmaculada Alarcón3,
  4. Anahy María Brandy-García4,
  5. Íñigo Rúa-Figueroa1,
  6. Estibaliz Loza2,
  7. Loreto Carmona2
  1. 1 Rheumatology, Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas de Gran Canaria, Spain
  2. 2 Institute for Musculoskeletal Health, Madrid, Spain
  3. 3 Biochemical Department, Autoimmunity Laboratory, Las Palmas de Gran Canaria, Spain
  4. 4 Rheumatology Department, Hospital Universitario Central de Asturias, Oviedo, Spain
  1. Correspondence to Dr Martin Greco, Rheumatology, Hospital Universitario de Gran Canaria Dr Negrin, Las Palmas de Gran Canaria 35010, Spain; martin-greco{at}hotmail.com

https://doi.org/10.1136/annrheumdis-2019-215766

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We have recently published a retrospective two centres study of 37 patients with clinical suspicion of idiopathic inflammatory myopathies (IIM) or antisynthetase syndrome (ASSD), and antiaminoacyl-transfer RNA synthetase (ARS) autoantibodies in the myositis immunoblot. In it, we discussed the role of the ARS in the IIM and the ASSD classification criteria, and a possible overlapping between both of them.1

    Regarding the detection of ARS, previous studies have shown differences in the specificity between different commercial assays; thus, in agreement with the highly appropriate commentaries raised by Knitza et al on our report, we consider that a careful interpretation of them is mandatory.2 3 In this way, in a recent review Damoiseaux et al proposed that to safeguard a high specificity of myositis-specific autoantibodies in multispecific-assays, it could be useful1: to establish adequate cut-off values in the immunoblot2; to correlate the results with another monospecific-assay (ie, ELISA …

    View Full Text

    Linked Articles